

Medicines and Healthcare products Regulatory Agency

MANUFACTURER'S AUTHORISATION

| | |
|---------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------|
| 1: Authorisation Number | UK MIA(IMP) 32611 |
| 2: Name of authorisation holder | IMPERIAL COLLEGE HEALTHCARE NHS TRUST |
| 3: Address(es) of manufacturing site(s) | JOHN GOLDMAN CENTRE FOR CELLULAR THERAPY, HAMMERSMITH HOSPITAL, DU CANE ROAD, LONDON, W12 0HS, UNITED KINGDOM |
| 4: Legally registered address of authorisation holder | IMPERIAL COLLEGE HEALTHCARE NHS TRUST, HAMMERSMITH HOSPITAL, DU CANE ROAD, LONDON, W12 0HS, UNITED KINGDOM |
| 5: Scope of authorisation and dosage forms | ANNEX 1 and/ or ANNEX 2 |
| 6: Legal Basis of authorisation | Part 6 of The Medicines for Human Use (Clinical Trials) Regulations 2004 [SI 2004/1031] |
| 7: Name of responsible officer of the competent authority of the member state granting the manufacturing authorisation | Confidential |
| 8: Authorisation Date | 17/12/2020 |
| 9: Annexes attached | Annex 1 and/or Annex 2 |

SCOPE OF AUTHORISATION

Annex 2

Name and address of the site:

**JOHN GOLDMAN CENTRE FOR CELLULAR THERAPY, HAMMERSMITH HOSPITAL, DU CANE ROAD, LONDON, W12 0HS,
UNITED KINGDOM**

| |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Human Investigational Medicinal Products |
| Authorised Operations |
| MANUFACTURING OPERATIONS (according to part 1) |
| Part 1 - MANUFACTURING OPERATIONS [1.1] Sterile Investigational Medicinal Products [1.1.1] Aseptically prepared (processing operations for the following dosage forms) [1.1.1.4] Small volume liquids [1.3] Biological investigational medicinal products [1.3.1] Biological medicinal products [1.3.1.1] Blood products [1.3.1.2] Immunological products |

[1.3.1.3] Cell therapy products

[1.5] Packaging

[1.5.2] Secondary packaging

[1.6] Quality control testing

[1.6.4] Biological